PDCD1 and neoplasm: The potential use of immunotherapy was exemplified by an exceptional response observed upon treatment with Vemurafenib (BRAFV600E inhibitor) and Nivolumab (human IgG4 anti-monoclonal PD-1 antibody) for tumor harboring BRAF mutation and PDL-1 positivity [90].